Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications

Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications

The pharmaceutical industry’s development of therapeutic medications for the treatment of Parkinson’s disease (PD) endures, as a result of the continuing need for better agents, and the increased clinical demand due to the aging population. Each new drug offers advantages and disadvantages to patien...

Full description

Bibliographic Details
Main Authors:	Massimo S. Fiandaca, Howard J. Federoff, Krystof S. Bankiewicz
Format:	Article
Language:	English
Published:	MDPI AG 2012-06-01
Series:	Pharmaceuticals
Subjects:	convection-enhanced delivery enzyme-replacement therapy gene therapy neurotrophic factor Parkinson’s disease viral vector
Online Access:	http://www.mdpi.com/1424-8247/5/6/553

Similar Items

The Use of Convection-Enhanced Delivery with Liposomal Toxins in Neurooncology
by: Mitchel S. Berger, et al.
Published: (2011-03-01)

Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease
by: Julia Tereshchenko, et al.
Published: (2014-05-01)

Efficacy of convection enhanced delivery of MTX110 (soluble panobinostat) in preclinical Diffuse Intrinsic Pontine Glioma models using metabolic hyperpolarized 13C imaging
by: Justyna M. Przystal, et al.
Published: (2023-12-01)

The Future of GDNF in Parkinson's Disease
by: Fredric P. Manfredsson, et al.
Published: (2020-12-01)

Gene Therapy Developments for Pompe Disease
by: Zeenath Unnisa, et al.
Published: (2022-01-01)

Special Issue: Gene Therapy with Emphasis on RNA Interference
by: Kenneth Lundstrom
Published: (2015-08-01)

Design and Validation of a Multi-Point Injection Technology for MR-Guided Convection Enhanced Delivery in the Brain
by: Kayla Prezelski, et al.
Published: (2021-10-01)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
by: Whiteman DAH, et al.
Published: (2017-08-01)

GABAergic Gene Regulatory Elements Used in Adeno-Associated Viral Vectors
by: Robert Duba-Kiss, et al.
Published: (2021-10-01)

Integrated robotics platform with haptic control differentiates subjects with Parkinson’s disease from controls and quantifies the motor effects of levodopa
by: Pauline Gaprielian, et al.
Published: (2019-10-01)

Current State of Human Gene Therapy: Approved Products and Vectors
by: Aladdin Y. Shchaslyvyi, et al.
Published: (2023-10-01)

Erythrocytes as Carriers of Therapeutic Enzymes
by: Bridget E. Bax
Published: (2020-05-01)

Limitations of Clinical Application of siRNA Delivery Based on Non-Viral Vectors
by: Reza Ghavimi, et al.
Published: (2014-04-01)

Enhanced gene transfection efficiency by low-dose 25 kDa polyethylenimine by the assistance of 1.8 kDa polyethylenimine
by: Hui Zhang, et al.
Published: (2018-01-01)

Peptide-Based Vectors for Gene Delivery
by: Juan Yang, et al.
Published: (2023-08-01)

CRISPR/Cas systems: Delivery and application in gene therapy
by: Jie Huang, et al.
Published: (2022-11-01)

Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies
by: Breanne Caffery, et al.
Published: (2019-01-01)

Gene therapy for Huntington's disease
by: Shilpa Ramaswamy, et al.
Published: (2012-11-01)

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease
by: Raymond T. Bartus, et al.
Published: (2011-10-01)

Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC
by: Claire O’Leary, et al.
Published: (2023-07-01)

Non-toxic HSC Transplantation-Based Macrophage/Microglia-Mediated GDNF Delivery for Parkinson’s Disease
by: Cang Chen, et al.
Published: (2020-06-01)

Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy
by: Paweł Dubiela, et al.
Published: (2023-04-01)

Targeting Mitochondrial Complex I Deficiency in MPP+/MPTP-induced Parkinson’s Disease Cell Culture and Mouse Models by Transducing Yeast NDI1 Gene
by: Hongzhi Li, et al.
Published: (2024-04-01)

Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review
by: Muhammad Hammad Butt, et al.
Published: (2022-07-01)

The challenge of vector development in gene therapy
by: S.U. Dani
Published: (1999-02-01)

Biodegradable Polymers for Gene-Delivery Applications
by: Chen CK, et al.
Published: (2020-03-01)

Efficacy and Safety of Pancreas-Targeted Hydrodynamic Gene Delivery in Rats
by: Kohei Ogawa, et al.
Published: (2017-12-01)

A compendium of preparation and application of stem cells in Parkinson’s Disease: current status and future prospects
by: Yan eShen, et al.
Published: (2016-05-01)

Adeno-associated viral vector-mediated gene transfer of brain-derived neurotrophic factor reverses atrophy of rubrospinal neurons following both acute and chronic spinal cord injury
by: Marc J Ruitenberg, et al.
Published: (2004-03-01)

State-of-the-art review of the clinical research on menopause and hormone replacement therapy association with Parkinson’s disease: What meta-analysis studies cannot tell us
by: Santiago R. Unda, et al.
Published: (2022-10-01)

Rehabilitation in Parkinson’s disease: Current status and future directions
by: Divyani Garg, et al.
Published: (2020-01-01)

THE INFLUENCE OF PHYSICAL ACTIVITY ON THE IMPROVEMENT OF MOTOR FUNCTIONING IN PEOPLE WITH PARKINSON’S DISEASE
by: Anna Marszałek, et al.
Published: (2022-10-01)

Editorial: Advanced (gene and cell) therapies for central nervous system applications
by: Liliana Mendonça, et al.
Published: (2023-02-01)

Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
by: Andrew Dawson, et al.
Published: (2023-01-01)

Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
by: Malte Lenders, et al.
Published: (2018-09-01)

Enzyme replacement therapies: what is the best option?
by: Azam Safary, et al.
Published: (2018-05-01)

Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy
by: Adriana Aurelia Chis, et al.
Published: (2021-10-01)

Lentiviral Vectors for Ocular Gene Therapy
by: Yvan Arsenijevic, et al.
Published: (2022-07-01)

How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?
by: Myriam Sainz-Ramos, et al.
Published: (2021-07-01)

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review
by: Liangnan Tong, et al.
Published: (2023-02-01)